selected scholarly activity
-
conferences
- Demographic Differences Between Consenting versus Non Consenting Participants for Biospecimen Collection on NRG Prostate Cancer Trials. International Journal of Radiation Oncology Biology Physics. E543-E544. 2024
- Individual patient data analysis of salvage radiotherapy trials: RTOG 0534 and GETUG-AFU 16. Radiotherapy and Oncology. S2426-S2427. 2024
- Impact of Testosterone Recovery on Clinical Outcomes of Patients Treated with Salvage Radiotherapy and Androgen Suppression: A Secondary Analysis of the NRG/RTOG 0534 Sport Phase 3 Trial. International Journal of Radiation Oncology Biology Physics. S82-S83. 2023
- Long-Term Outcomes of NRG/RTOG 0126, a Randomized Trial of High Dose (79.2 Gy) vs. Standard Dose (70.2 Gy) Radiation Therapy (RT) for Men with Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics. S4-S5. 2023
- Quality of Life Results of Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy: NRG Oncology/RTOG 0534 SPPORT. International Journal of Radiation Oncology Biology Physics. S24-S24. 2023
- EVALUATION OF VOLUMETRIC RESPONSE ASSESSMENT FROM STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR RENAL CELL CARCINOMA (RCC). Radiotherapy and Oncology. S67-S67. 2023
- PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY FOR PATIENTS WITH RECURRENT PROSTATE CANCER (PREP) - A PROSPECTIVE, MULTICENTRE REGISTRY. Radiotherapy and Oncology. S108-S108. 2023
- STEREOTACTIC BODY RADIATION THERAPY (SBRT) AND HYPO-FRACTIONATED RADIATION THERAPY (HFRT) OUTCOMES FOR LOW AND INTERMEDIATE-RISK PROSTATE CANCER (PRCA): EXPERIENCE AT TWO ONTARIO CENTRES. Radiotherapy and Oncology. S53-S53. 2023
- Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.. Journal of Clinical Oncology. 2023
- The Influence of Pelvic Lymph Node Dissection Volumes on Clinical Outcomes in NRG/RTOG 0534. International Journal of Radiation Oncology Biology Physics. S36-S36. 2022
- CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570). Journal of Clinical Oncology. 2022
- Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601.. Journal of Clinical Oncology. 265-265. 2022
- A Prospective Provincial PSMA-PET Registry for Recurrent Prostate Cancer: Preliminary results. International Journal of Radiation Oncology Biology Physics. e877-e878. 2020
- Evaluation Of A Deep Learning-Based Auto-Segmentation Method For Quality Assurance Of Both Male And Female Pelvic Organ-At-Risk Contours In NCTN Clinical Trials. International Journal of Radiation Oncology Biology Physics. e769-e769. 2020
- Impact of Pelvic Intensity-modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. e250-e250. 2020
- Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. International Journal of Radiation Oncology Biology Physics. S63-S64. 2020
- Patient Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase II Study Evaluating 2 Ultrahypofractionated Regimens (UHR) for Prostate Cancer (CaP). International Journal of Radiation Oncology Biology Physics. S119-S120. 2020
- Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial. Journal of Clinical Oncology. 2020
- IMPACT OF PELVIC INTENSITY-MODULATED RADIOTHERAPY (IMRT) ON LYMPH NODE COVERAGE AND DOSE TO CRITICAL ORGANS, COMPARE TO THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY (3D-CRT), IN LOCALIZED HIGH-RISK PROSTATE CANCER. Radiotherapy and Oncology. S68-S68. 2019
- IMPROVEMENTS IN FREEDOM FROM PROGRESSION WITH SHORT TERM ANDROGEN DEPRIVATION THERAPY AND PELVIC LYMPH NODE TREATMENT ADDED TO PROSTATE BED SALVAGE RADIOTHERAPY: THE NRG ONCOLOGY/RTOG 0534 SPPORT TRIAL. Journal of Urology. E1054-E1055. 2019
- Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial. International Journal of Radiation Oncology Biology Physics. 1605-1605. 2018
- Outcomes of Tri-Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics. e89-e89. 2018
- Patient-Reported Quality of Life Following Stereotactic Body Radiation Therapy for Primary Kidney Cancer: Results from a Prospective Cohort Study. International Journal of Radiation Oncology Biology Physics. e93-e94. 2018
- Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials. International Journal of Radiation Oncology Biology Physics. S148-S148. 2018
- Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.. Journal of Clinical Oncology. 5018-5018. 2018
- Long-Term Outcomes of Microinvasive Breast Cancer in the Canadian Hypofractionation Trial. International Journal of Radiation Oncology Biology Physics. S56-S57. 2017
- Randomized Study of Quality of Life in Patients with High-Risk Prostate Cancer Undergoing Radiotherapy: Role of Pelvic Nodal IMRT. International Journal of Radiation Oncology Biology Physics. E211-E212. 2017
- MP14-04 CARDIOVASCULAR DISEASE CHARACTERISTICS OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS: FINDINGS FROM THE PILOT PHASE OF RADICAL PC: A PROSPECTIVE STUDY OF CARDIOVASCULAR DISEASE IN MEN WITH PROSTATE CANCER. Investigative Urology. E163-E163. 2017
- Investigation Into the Feasibility of Having Uniform Compliance Dosimetric Criteria Across Radiation Therapy Treatment Modalities for NRG Oncology/RTOG 0938 by Using Machine Learning. International Journal of Radiation Oncology Biology Physics. E230-E231. 2016
- COMPARISON OF EXISTING RISK STRATIFICATION TOOLS FOR LOCALIZED PROSTATE CANCER. Radiotherapy and Oncology. S13-S13. 2016
- EXTERNAL VALIDATION OF THE PROCARS NOMOGRAMS FOR LOCALIZED PROSTATE CANCER. Radiotherapy and Oncology. S75-S75. 2016
- A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer.. Journal of Clinical Oncology. 5003-5003. 2016
- NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.. Journal of Clinical Oncology. 3-3. 2016
- Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).. Journal of Clinical Oncology. 27-27. 2016
- The RADICAL-PC trial.. Journal of Clinical Oncology. 178-178. 2016
- Patient-Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase 2 Study Evaluating 2 Ultrahypofractionated Regimens (UHRs) for Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 2-2. 2016
- Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA. International Journal of Radiation Oncology Biology Physics. 3-3. 2016
- Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics. S59-S59. 2015
- Nadir Prostate-Specific Antigen After Neoadjuvant Androgen Suppression (AS) in Prostate Cancer Patients Receiving Short-term AS and Radiation Therapy: Pooled Analysis of Four NRG Oncology/RTOG Randomized Clinical Trials. International Journal of Radiation Oncology Biology Physics. S46-S46. 2015
- Post–Biochemical Failure Risk Stratification to Predict Survival in Prostate Cancer: A Recursive Partitioning Analysis. International Journal of Radiation Oncology Biology Physics. E192-E192. 2015
- Abstract 4346: Prognostic gene signature for intermediate risk prostate cancer. Cancer Research. 4346-4346. 2015
- Comparison of LDR Brachytherapy Versus External Beam Radiation Therapy for Low- And Intermediate-Risk Prostate Cancer: A Propensity-Score Matched Analysis. International Journal of Radiation Oncology Biology Physics. S414-S415. 2014
- Stereotactic Ablative Radiation Therapy Versus Low-Dose-Rate Brachytherapy: A Propensity Matched Analysis of Canadian Data. International Journal of Radiation Oncology Biology Physics. S424-S424. 2014
- The Significance of p16 and p53 Expression on Clinical Outcome in Patients with Anal Cancer Treated with Chemoradiation Therapy: An Analysis of RTOG 98-11. International Journal of Radiation Oncology Biology Physics. S32-S32. 2014
- Acute and Late Urinary Toxicity After Radiation Therapy in Men With and Without an Intact Prostate Gland: A Secondary Analysis of RTOG 9408 and 9601 Suggesting This Toxicity is Not Due to Bladder Injury. International Journal of Radiation Oncology Biology Physics. S14-S14. 2012
- The Prostate Cancer Risk Stratification (ProCaRS) Project: Database Construction and Outcome Analysis. International Journal of Radiation Oncology Biology Physics. S57-S57. 2012
- The Prostate Cancer Risk Stratification (ProCaRS) Project: Recursive Partitioning Risk Stratification Analysis. International Journal of Radiation Oncology Biology Physics. S181-S182. 2012
- Double-blinded, Placebo-controlled Randomized Study Evaluating the Efficacy of Risedronate to Prevent the Loss of Bone Mineral Density in Non-metastatic Prostate Cancer Patients Undergoing Radiotherapy Plus 2-3 Years of Androgen Ablation Therapy. International Journal of Radiation Oncology Biology Physics. S42-S42. 2011
- 536 oral RTOG 9601: SALVAGE RT & ANTI-ANDROGEN THERAPY IN PROSTATE CANCER PATIENTS WITH ELEVATED PSA AFTER SURGERY. Radiotherapy and Oncology. S219-S219. 2011
- Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels. Journal of Clinical Oncology. 2011
- Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels. International Journal of Radiation Oncology Biology Physics. S27-S27. 2010
- FEASIBILITY OF BONE MARROW SPARING USING INTENSITY MODULATED RADIOTHERAPY IN A PATIENT WITH INTERMEDIATE RISK PROSTATE CANCER AND COMPROMISED PLATELET COUNT DUE TO CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA.. Radiotherapy and Oncology. S500-S501. 2010
- ACUTE URINARY MORBIDITY OF RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: DO PATIENTS UNDERGOING CONFORMAL RADIATION THERAPY WITH IMPLANTED GOLD SEEDS HAVE MORE URINARY SYMPTOMS DURING RADIATION THERAPY?. Radiotherapy and Oncology. S52-S53. 2008
- Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer: Results of the Randomized MRC ASTEC and NCIC CTG EN.5 Trials, A Systematic Review and Meta-analysis. International Journal of Radiation Oncology Biology Physics. S353-S354. 2008
- IMPACT OF BLADDER FILLING (FULL OR EMPTY) ON DOSE VOLUME HISTOGRAMS IN RADIATION PLANNING FOR POST-PROSTATECTOMY PATIENTS. Radiotherapy and Oncology. S54-S54. 2008
- INFLUENCE OF GOLD SEED IMPLANTATION ON DEFINING TARGET VOLUMES FOR CONFORMAL RADIOTHERAPY OF PROSTATE CANCER. Radiotherapy and Oncology. S51-S51. 2008
- INVESTIGATING RESVERATROL IN COMBINATION WITH RADIATION IN PROSTATE CANCER. Radiotherapy and Oncology. S37-S37. 2008
- Influence of Gold Seed Implantation on Defining Target Volumes for Conformal Radiotherapy of Prostate Cancer. International Journal of Radiation Oncology Biology Physics. S322-S322. 2008
- 226 Timing of androgen deprivation therapy after radical radiotherapy failure — A survey of Canadian practitioners. Radiotherapy and Oncology. S66-S66. 2006
- 34 Phase 2 study of neoadjuvant docetaxel and androgen suppression (AS) Plus Radiation Therapy (RT) for high risk localized prostate cancer (HRLCaP). Radiotherapy and Oncology. S10-S11. 2006
- Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP).. Journal of Clinical Oncology. 249S-249S. 2006
- 121 The use of bisphosphonates in men with hormone-refractory prostate cancer: A systematic review of randomized trials. Radiotherapy and Oncology. S36-S36. 2005
- 14 Randomized Trial Comparing Iridium Plus External-Beam Radiation Therapy with External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Radiotherapy and Oncology. S5-S5. 2005
- 201 Anatomical variables may determine the value of IMRT in intermediate risk prostate cancer: A dosimetric evaluation between IMRT and 3D-CRT PLANS. Radiotherapy and Oncology. S59-S59. 2005
- A randomized trial comparing a combination of iridium implant and external beam radiation to external beam radiation alone for patients with locally advanced prostate cancer. International Journal of Radiation Oncology Biology Physics. S448-S448. 2004
- Anatomical variables may determine the value of IMRT in intermediate risk prostate cancer: A dosimetric evaluation between IMRT and 3D-CRT plans.. Radiotherapy and Oncology. S38-S38. 2004
- Anatomical variables may determine the value of IMRT in intermediate risk prostate cancer: A dosimetric evaluation between IMRT and 3D-Crt plans. Radiotherapy and Oncology. S31-S31. 2004
- Correlation between two surrogate outcomes: Post-radiotherapy biopsy (PRB) and PSA failure (BCF): Results from a randomized hypofractionated study in localized prostate cancer. Radiotherapy and Oncology. S21-S21. 2004
- Post radiotherapy biopsy correlation with PSA failure: Results from a randomized hypofractionated study in localized prostate cancer. International Journal of Radiation Oncology Biology Physics. S171-S171. 2004
- Role of neoadjuvant chemotherapy (NAC) in transitional cell carcinoma (TCC): A systematic review. Journal of Urology. 383-383. 2003
- The assessment of post-radiation prostatic needle biopsies for residual adenocarcinoma: A study of interobserver agreement. Modern Pathology. 166A-166A. 2002
- The assessment of post-radiation prostatic needle biopsies for residual adenocarcinoma: A study of interobserver agreement. Laboratory Investigation. 166A-166A. 2002
- PRIMITIVE NEUROECTODERMAL TUMORS OF THE UTERUS - A REPORT OF 4 CASES WITH IMMUNOHISTOCHEMICAL, ULTRASTRUCTURAL AND HISTOGENETIC OBSERVATIONS. Laboratory Investigation. A63-A63. 1992
- HER-2/NEU ONCOGENE AS A PROGNOSTIC FACTOR IN NODE NEGATIVE BREAST-CANCER. Breast Cancer Research and Treatment. 109-109. 1988
- THE INFLUENCE OF EXOGENOUS HORMONES ON ESTROGEN AND PROGESTERONE RECEPTORS IN PRIMARY BREAST-CARCINOMA. Breast Cancer Research and Treatment. 135-135. 1988
- LYMPH-NODE EVALUATION USING COMPUTED-TOMOGRAPHY AND IMMUNOLYMPHOSCINTIGRAPHY IN PROSTATE-CANCER. Clinical Radiology. 352-352. 1988
- CLINICAL-EXPERIENCE WITH A 27 MHZ HYPERTHERMIA UNIT FOR THE TREATMENT OF CANCER. International Journal of Hyperthermia. 572-572. 1987
- INTRACAVITARY RADIOTHERAPY IN GYNECOLOGICAL MALIGNANCY - THE USE OF CT TO CHECK DOSIMETRY. Clinical and Investigative Medicine. B113-B113. 1987
- THE RELATIONSHIP OF THE BLADDER AND THE CERVIX IN PATIENTS UNDERGOING INTRACAVITARY THERAPY. British Journal of Radiology. 845-845. 1986
-
journal articles
- Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium.. The Lancet Oncology. 26:459-469. 2025
- The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials.. The Lancet Oncology. 26:378-386. 2025
- Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial.. Journal of Clinical Oncology. 43. 2025
- Hypofractionated radiotherapy for prostate cancer (HYDRA): An individual patient data meta-analysis of randomized trials in the MARCAP consortium.. Journal of Clinical Oncology. 43. 2025
- The prognostic impact of prostate-specific antigen at 6 months after post-prostatectomy radiotherapy: An individual patient data analysis of two NRG oncology randomized trials.. Journal of Clinical Oncology. 43. 2025
- Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for Unfavorable Intermediate and High-Risk Prostate Cancer; Early Results of PBS: A Phase II Randomized Trial (NCT03380806). International Journal of Radiation Oncology Biology Physics. 120:S126-S127. 2024
- Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics. 119:832-837. 2024
- Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials. Journal of Clinical Oncology. 42:2132-2138. 2024
- Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. The Lancet. 403:2405-2415. 2024
- Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. The Lancet. 403:2416-2425. 2024
- 1359: Individual patient data analysis of salvage radiotherapy trials: RTOG 0534 and GETUG-AFU 16. Radiotherapy and Oncology. 194:s2426-s2427. 2024
- Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers. Prostate. 84:193-202. 2024
- Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.. Journal of Clinical Oncology. 42:320-320. 2024
- Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC). International Journal of Radiation Oncology Biology Physics. 117:e434-e434. 2023
- 114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres. Radiotherapy and Oncology. 186:S53-S53. 2023
- 147 Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC). Radiotherapy and Oncology. 186:S67-S67. 2023
- Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 116:770-778. 2023
- Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.. Journal of Clinical Oncology. 41:5002-5002. 2023
- Long-term outcomes and effects of hypofractionated radiotherapy in microinvasive breast cancer: Analysis from a randomized trial. Breast. 68:189-193. 2023
- Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.. Journal of Clinical Oncology. 41:363-363. 2023
- Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with 18F-DCFPyL PSMA-PET: A regional cohort analysis.. Journal of Clinical Oncology. 41:45-45. 2023
- Patterns of failure with 18F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.. Journal of Clinical Oncology. 41:309-309. 2023
- Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review. Therapeutic Advances in Medical Oncology. 15:175883592311528-175883592311528. 2023
- Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. Journal of Clinical Oncology. 40:3172-3179. 2022
-
Salvage radiotherapy following
HiFU : An institutional series and literature review. Journal of Medical Imaging and Radiation Oncology. 66:847-852. 2022 - The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. The Lancet. 399:1886-1901. 2022
- The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments. Clinical Genitourinary Cancer. 20:e25-e38. 2022
- 151: Prostate SBRT Boost Radiotherapy (PBS Trial): A Randomized Phase II Trial of SBRT Versus Conventionally-Fractionated Radiotherapy Boost Following Pelvic Radiotherapy in High-Risk Prostate Cancer. Radiotherapy and Oncology. 163:S64-S64. 2021
- 18: PSMA-PET-Based Response Assessment of Metastatic Prostate Cancer Response to Radiotherapy: A Case Series. Radiotherapy and Oncology. 163:S11-S11. 2021
- Change to Open Access Status. JAMA Oncology. 7:639-639. 2021
- Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. JAMA Oncology. 7:544-544. 2021
- Reply by Authors. Investigative Urology. 205:345-345. 2021
- Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. Journal of the Canadian Urological Association. 14:E588-E593. 2020
- 206: A Randomized Phase Ii Trial of Prostate Boost Irradiation with Stereotactic Body Radiotherapy (SBRT) in High-Risk Prostate Cancer. The Pbs Trial. Radiotherapy and Oncology. 150:S87-S88. 2020
- 62: A Prospective Provincial Psma-Pet Registry for Recurrent Prostate Cancer: Preliminary Results. Radiotherapy and Oncology. 150:S30-S30. 2020
- Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. Investigative Urology. 204:416-426. 2020
- A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806). Clinical Genitourinary Cancer. 18:e410-e415. 2020
- Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics. 107:943-948. 2020
- Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. Investigative Urology. 203:1109-1116. 2020
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Journal of the Canadian Urological Association. 14:123-130. 2020
- Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Journal of the Canadian Urological Association. 14:E115-E125. 2020
- Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.. Journal of Clinical Oncology. 38:276-276. 2020
- Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. Asian Journal of Andrology. 22:437-437. 2020
- 146 A Comparison of Stereotactic Body Radiotherapy Modalities: Volumetric Modulated Arc Therapy Versus Intensity Modulated Radiation Therapy in Treatment of Kidney Cancer. Radiotherapy and Oncology. 139:S63-S63. 2019
- 158 Impact of Pelvic Intensity-Modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer. Radiotherapy and Oncology. 139:S68-S68. 2019
- Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. International Journal of Radiation Oncology Biology Physics. 104:1057-1065. 2019
- The evolution of fractionated prostate cancer radiotherapy. The Lancet. 394:361-362. 2019
- MP72-01 IMPROVEMENTS IN FREEDOM FROM PROGRESSION WITH SHORT TERM ANDROGEN DEPRIVATION THERAPY AND PELVIC LYMPH NODE TREATMENT ADDED TO PROSTATE BED SALVAGE RADIOTHERAPY: THE NRG ONCOLOGY/RTOG 0534 SPPORT TRIAL. Investigative Urology. 201. 2019
- Reply to J. David et al. Journal of Clinical Oncology. 37:441-441. 2019
- Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis. Journal of the Canadian Urological Association. 13:15-23. 2019
- Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT. BMC Cancer. 18:1031. 2018
- Prostate Cancer Radiotherapy: An Evolving Paradigm. Journal of Clinical Oncology. 36:2909-2913. 2018
- Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 102:287-295. 2018
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Journal of Clinical Oncology. 35:3097-3104. 2017
- Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology. 35:1884-1890. 2017
- Supplementary data: External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. Journal of the Canadian Urological Association. 11:126-126. 2017
- Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data. Clinical Oncology. 29:161-170. 2017
- Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. New England Journal of Medicine. 376:417-428. 2017
- External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. Journal of the Canadian Urological Association. 11:94-94. 2017
- Profit (Prostate Fractionated Irradiation Trial) : résultats d’une étude internationale randomisée comparant deux schémas d’irradiation des cancers de prostate de risque intermédiaire. The French Journal of Urology. 26:793-794. 2016
- Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urologic Oncology: Seminars and Original Investigations. 34:430.e1-430.e7. 2016
- Prostate Fractionated Irradiation Trial (PROFIT) : résultats d’une étude internationale randomisée comparant deux schémas d’irradiation des cancers de prostate de risque intermédiaire. Cancer/Radiotherapie. 20:710-710. 2016
- The Technique, Resources and Costs of Stereotactic Body Radiotherapy of Prostate Cancer. Technology in Cancer Research and Treatment. 15:171-178. 2016
- Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation. Oncology Reports. 34:1968-1976. 2015
- Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer. Cureus. 7:e276. 2015
- Brachytherapy Improves Biochemical Failure–Free Survival in Low- and Intermediate-Risk Prostate Cancer Compared With Conventionally Fractionated External Beam Radiation Therapy: A Propensity Score Matched Analysis. International Journal of Radiation Oncology Biology Physics. 91:505-516. 2015
- Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910. Journal of Clinical Oncology. 33:332-339. 2015
- Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials. Journal of the National Cancer Institute. 106:dju132. 2014
- The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis. Journal of the National Comprehensive Cancer Network : JNCCN. 12:60-69. 2014
- The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. Radiotherapy and Oncology. 109:204-210. 2013
- Randomized, Double-Blinded, Placebo-Controlled, Trial of Risedronate for the Prevention of Bone Mineral Density Loss in Nonmetastatic Prostate Cancer Patients Receiving Radiation Therapy Plus Androgen Deprivation Therapy. International Journal of Radiation Oncology Biology Physics. 85:1239-1245. 2013
- Pre-treatment risk stratification of prostate cancer patients: A critical review. Journal of the Canadian Urological Association. 6:121-127. 2012
- Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiation Oncology. 6:144. 2011
- High-intensity Focused Ultrasound for Prostate Cancer: a Systematic Review. Clinical Oncology. 23:117-127. 2011
- Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels.. Journal of Clinical Oncology. 29:1-1. 2011
- High-intensity focused ultrasound for prostate cancer: a practice guideline. Journal of the Canadian Urological Association. 4:232-232. 2010
- Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer. New England Journal of Medicine. 362:513-520. 2010
- Management of Stage I Seminomatous Testicular Cancer: a Systematic Review. Clinical Oncology. 22:6-16. 2010
- Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. Journal of the Canadian Urological Association. 3:460-460. 2009
- In favour of bladder preservation using combined modality treatment. Journal of the Canadian Urological Association. 3:412-412. 2009
- Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. The Lancet. 373:137-146. 2009
- Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting. Journal of the Canadian Urological Association. 2:500-500. 2008
- Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: A systematic review and meta-analysis. Radiotherapy and Oncology. 88:1-9. 2008
- Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement. Journal of the Canadian Urological Association. 2:95-95. 2008
- Ontario Cervical Cancer Screening Clinical Practice Guidelines. Journal of Obstetrics and Gynaecology Canada. 29:344-353. 2007
- Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer. 6:112. 2006
- Adjuvant radiotherapy in women with stage I endometrial cancer: A systematic review. Gynecologic Oncology. 102:361-368. 2006
- The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials.. Canadian Journal of Urology. 13:3180-3188. 2006
- Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP). Journal of Clinical Oncology. 24:4631-4631. 2006
- Follow-up after primary therapy for endometrial cancer: A systematic review. Gynecologic Oncology. 101:520-529. 2006
- Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer—A Systematic Review. Current Oncology. 13:81-93. 2006
- GU radiation oncologists consensus on bone loss from androgen deprivation.. Canadian Journal of Urology. 13:2962-2966. 2006
- Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer. Journal of Clinical Oncology. 23:6132-6138. 2005
- Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Journal of Clinical Oncology. 23:1192-1199. 2005
- Prostate cancer radiotherapy 2002: the way forward.. Canadian Journal of Urology. 12:2521-2531. 2005
- A randomized trial comparing a combination of iridium implant and external beam radiation to external beam radiation alone for patients with locally advanced prostate cancer. International Journal of Radiation Oncology Biology Physics. 60:S448-S448. 2004
- Post radiotherapy biopsy correlation with PSA failure: Results from a randomized hypofractionated study in localized prostate cancer. International Journal of Radiation Oncology Biology Physics. 60:S171-S171. 2004
- Screening Postmenopausal Women for Ovarian Cancer: A Systematic Review. Journal of Obstetrics and Gynaecology Canada. 26:717-728. 2004
- Accuracy of ultrasound in localization of breast boost field. Radiotherapy and Oncology. 72:61-66. 2004
- BASELINE STAGING OF NEWLY DIAGNOSED PROSTATE CANCER: A SUMMARY OF THE LITERATURE. Investigative Urology. 171:2122-2127. 2004
- Combined gamma‐irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin. International Journal of Radiation Biology. 80:291-299. 2004
- Concurrent Cisplatin-based Chemotherapy plus Radiotherapy for Cervical Cancer:. Clinical Oncology. 16:160-161. 2004
- Neoadjuvant Chemotherapy for Transitional Cell Carcinoma of the Bladder: A Systematic Review and Meta-Analysis. Investigative Urology. 171:561-569. 2004
- A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology Biology Physics. 57:S126-S126. 2003
- Process and outcome of real-time radiotherapy review in a national study of prostate cancer radiotherapy. International Journal of Radiation Oncology Biology Physics. 54:276-277. 2002
- The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer – a systematic review. Radiotherapy and Oncology. 64:239-250. 2002
- Randomized Trial of Breast Irradiation Schedules After Lumpectomy for Women With Lymph Node-Negative Breast Cancer. Journal of the National Cancer Institute. 94:1143-1150. 2002
- Concurrent Cisplatin-based Chemotherapy plus Radiotherapy for Cervical Cancer–a Meta-analysis. Clinical Oncology. 14:203-212. 2002
- Prostate cancer: risk categories and role of hormones and radiotherapy.. Canadian Journal of Urology. 9 Suppl 1:26-29. 2002
- Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.. Journal of Clinical Oncology. 20:966-972. 2002
- Seed implant brachytherapy for prostate cancer - Reply. CANADIAN MEDICAL ASSOCIATION JOURNAL. 165:1004-1004. 2001
- Controversies in prostate cancer radiotherapy: consensus development.. Canadian Journal of Urology. 8:1314-1322. 2001
- Cutaneous Metastasis of Papillary Serous Uterine Cancer. Gynecologic Oncology. 82:208-211. 2001
- Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 164:975-981. 2001
- Surveillance programs for early stage non-seminomatous testicular cancer: a practice guideline.. Canadian Journal of Urology. 8:1184-1192. 2001
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Gynecology Cancer Working Group.. International Journal of Radiation Oncology Biology Physics. 51:58-59. 2001
- Use of topotecan in pre-treated recurrent or relapsed ovarian cancer patients. Current Oncology. 7:136-148. 2000
- Pre-exposure of human squamous carcinoma cells to low-doses of gamma-rays leads to an increased resistance to subsequent low-dose cisplatin treatment. International Journal of Radiation Biology. 75:963-972. 1999
- Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.. Cancer Prevention and Control. 2:79-87. 1998
- A randomized trial comparing combination of iridium implant and external beam radiation vs. external beam radiation alone in node negative locally advanced cancer of the prostate: Preliminary report. International Journal of Radiation Oncology Biology Physics. 42:302-302. 1998
- Importance of the minimental status exam (MMSE) in the treatment of patients with brain metastases: A report from the radiation therapy oncology group protocol 9104. International Journal of Radiation Oncology Biology Physics. 42:261-261. 1998
- Reply. Gynecologic Oncology. 66:542-542. 1997
- A Phase II Study of Leuprolide in Advanced/Recurrent Endometrial Cancer. Gynecologic Oncology. 64:126-129. 1997
- 69 A randomized phase III study of accelerated hyperfractionation versus standard fractionation in patients with unresected brain metastasis: A report of radiation therapy oncology group (RTOG) 9104. International Journal of Radiation Oncology Biology Physics. 36:193-193. 1996
- Phase II Study to Evaluate the Toxicity and Efficacy of Concurrent Cisplatin and Radiation Therapy in the Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Cervix. Gynecologic Oncology. 58:38-41. 1995
- Patient preference for high or low dose rate brachytherapy in carcinoma of the cervix. Medical Dosimetry. 20:143-143. 1995
- Breast irradiation postlumpectomy: development and evaluation of a decision instrument.. Journal of Clinical Oncology. 13:847-853. 1995
- Patient preference for high or low dose rate brachytherapy in carcinoma of the cervix. Radiotherapy and Oncology. 33:187-194. 1994
- High dose rate versus low dose rate brachytherapy for squamous cell carcinoma of the cervix: an economic analysis. British Journal of Radiology. 67:1113-1120. 1994
- Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. International Journal of Radiation Oncology Biology Physics. 25:805-813. 1993
- Primitive neuroectodermal tumors of the uterus: A report of four cases. Human Pathology. 23:1120-1129. 1992
- The use of CT for selectron patients. Medical Dosimetry. 15:193-197. 1990
- Determination of human skin pain threshold using 27 MHz radiofrequency heating. British Journal of Radiology. 61:344-345. 1988
- The relationship between the bladder and the cervix in patients undergoing intracavitary therapy. British Journal of Radiology. 60:355-359. 1987
- Pre-treatment risk stratification of prostate cancer patients:A critical review. Journal of the Canadian Urological Association. 6.